KPV

Alpha-MSH: Pigmentation and Inflammation in One Hormone

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Alpha-melanocyte-stimulating hormone is a 13-residue peptide at 1,664.9 Da, derived from proopiomelanocortin. It drives pigmentation through melanocortin receptors and separately has well-described anti-inflammatory activity, which localises to its C-terminal tripeptide.

Key facts

Length
13 residues
Molecular weight
1,664.9 Da
Formula
C77H109N21O19S
PubChem CID
16133793
Precursor
Proopiomelanocortin (POMC)
Pigmentation via
Melanocortin-1 receptor
Anti-inflammatory region
C-terminal Lys-Pro-Val

Where it comes from

Alpha-MSH is cleaved from proopiomelanocortin, a precursor protein that also yields ACTH, beta-endorphin and other peptides. One gene product, several signalling molecules: the same architecture that produces GLP-1 and oxyntomodulin from proglucagon. Which peptides emerge depends on which processing enzymes are present in a given tissue.

The pigmentation function

Alpha-MSH acts on the melanocortin-1 receptor on melanocytes, stimulating melanin synthesis. This is the activity the hormone is named for and the one Melanotan II was designed to exploit. It is receptor-mediated, well characterised, and entirely separate from what the C-terminal tripeptide does.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

The anti-inflammatory function

Alpha-MSH also has described anti-inflammatory activity, reviewed by Luger and colleagues in the Annals of the New York Academy of Sciences in 2003 and by Brzoska and colleagues in 2010. Brzoska's title ('terminal signal') refers directly to the finding that this activity is carried by the hormone's C-terminal end rather than the receptor-binding core.

Why one hormone does two unrelated things

Different regions of the molecule. The core sequence engages melanocortin receptors and drives pigmentation; the C-terminal three residues carry anti-inflammatory activity through mechanisms that do not require the same receptor engagement. A single peptide with two functionally separable domains is not unusual, but it is unusually clean here.

The two fragments that followed

The separation produced two quite different research compounds. KPV takes the anti-inflammatory C-terminus without the pigmentation activity. Melanotan II takes the opposite approach: a cyclic analogue built around the melanocortin-receptor-binding portion, designed to maximise the pigmentation effect. Same parent hormone, opposite halves of its function.

Frequently asked questions

What does alpha-MSH do?

Two separable things: drives pigmentation through melanocortin receptors, and carries anti-inflammatory activity in its C-terminal region.

Where does it come from?

It is cleaved from proopiomelanocortin, the same precursor that yields ACTH and beta-endorphin.

How do KPV and Melanotan II relate?

Both derive from alpha-MSH but take opposite halves of its function, KPV the anti-inflammatory C-terminus and Melanotan II the pigmentation-driving core.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.